MARKET

CEMI

CEMI

Chembio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.980
-0.220
-5.24%
Closed 16:00 01/27 EST
OPEN
4.250
PREV CLOSE
4.200
HIGH
4.400
LOW
3.963
VOLUME
99.44K
TURNOVER
--
52 WEEK HIGH
7.90
52 WEEK LOW
3.750
MARKET CAP
69.91M
P/E (TTM)
-5.1501
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CEMI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CEMI News

  • Chembio Diagnostics Reports Pres, CEO John Sperzel To Resign; Gail Page Named Interim CEO
  • Benzinga.01/09 21:16
  • T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer
  • GlobeNewswire.01/09 21:15
  • Chembio Diagnostics Announces CEO Transition
  • GlobeNewswire.01/09 21:05
  • The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger
  • Benzinga.01/03 12:55

More

Industry

Pharmaceuticals
-0.42%
Pharmaceuticals & Medical Research
-0.51%

Hot Stocks

Name
Price
%Change

About CEMI

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
More

Webull offers Chembio Diagnostics Inc (CEMI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.